Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up
Schröder FH., Hugosson J., Roobol MJ., Tammela TLJ., Zappa M., Nelen V., Kwiatkowski M., Lujan M., Määttänen L., Lilja H., Denis LJ., Recker F., Paez A., Bangma CH., Carlsson S., Puliti D., Villers A., Rebillard X., Hakama M., Stenman UH., Kujala P., Taari K., Aus G., Huber A., Van Der Kwast TH., Van Schaik RHN., De Koning HJ., Moss SM., Auvinen A.
Background The European Randomised study of Screening for Prostate Cancer (ERSPC) has shown significant reductions in prostate cancer mortality after 9 years and 11 years of follow-up, but screening is controversial because of adverse events such as overdiagnosis. We provide updated results of mortality from prostate cancer with follow-up to 2010, with analyses truncated at 9, 11, and 13 years.